A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.

Charu Aggarwal,Alisha P Maity,Joshua M Bauml,Qi Long,Tomas Aleman,Christine Ciunci,Christopher D'Avella,Melissa Volpe,Evan Anderson,Lisa Mc Cormick Jones,Lova Sun,Aditi P Singh,Melina E Marmarelis,Roger B Cohen,Corey J Langer,Ravi Amaravadi

The oncologist（2023）

引用 0|浏览14

暂无评分

摘要

The combination of B + HCQ in second- or later-line treatment of patients with advanced KRAS-mutant NSCLC did not show significant antitumor activity. (ClinicalTrials.gov Identifier: NCT04735068).

查看译文

关键词

lung cancer,hydroxychloroquine,binimetinib,open-label,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要